Rocket Pharmaceuticals appoints Mark White as CMO; Schwartz shifts to Chief Gene Therapy Officer

ROCKET PHARMACEUTICALS, INC.

Mark White appointed Chief Medical Officer effective April 4, 2023; previously Global Franchise Head for Fasenra at AstraZeneca.
Jonathan Schwartz transitions to newly created Chief Gene Therapy Officer, focusing on gene therapy strategy and external opportunities.
White receives $450k base salary, 45% target bonus, and ~$2M equity grant (1/3 options, 2/3 RSUs) with standard vesting.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jonathan Schwartz

Chief Gene Therapy Officer

RCKT · ROCKET PHARMACEUTICALS, INC.

Effective: 2023-04-04
Filed: April 4, 2023, 7:59 PM ET

On April 4, 2023, Jonathan Schwartz transitioned from Chief Medical Officer of Rocket Pharmaceuticals, Inc. (the “ Company ”) to Chief Gene Therapy Officer,

Appointed

Mark White

Chief Medical Officer

RCKT · ROCKET PHARMACEUTICALS, INC.

Effective: 2023-04-04
Filed: April 4, 2023, 7:59 PM ET

Additionally, on April 4, 2023, Mark White joined the Company as its new Chief Medical Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jonathan Schwartz changed role as Chief Gene Therapy Officer at ROCKET PHARMACEUTICALS, INC..

Action: transitioned
Role: Chief Gene Therapy Officer

Exact text from the filing

On April 4, 2023, Jonathan Schwartz transitioned from Chief Medical Officer of Rocket Pharmaceuticals, Inc. (the “ Company ”) to Chief Gene Therapy Officer,

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark White was appointed as Chief Medical Officer at ROCKET PHARMACEUTICALS, INC..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

Additionally, on April 4, 2023, Mark White joined the Company as its new Chief Medical Officer.

View on SEC.gov

ROCKET PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-23-016314

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.